Erectile Dysfunction Drugs Market is expected to reach an estimated value of US$3.4 billion in 2019: Transparency Market Research.
Albany, NY, April 16, 2015 (GLOBE NEWSWIRE) — In a new report titled ‘ Erectile Dysfunction Drugs Market – Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 – 2019 ,’ published by Transparency Market Research, research analysts state that the global erectile dysfunction drugs market is expected to decline at a CAGR of 4.5% in the forecast period 2013 to 2019. This market was valued at US$4.3 billion in 2012 but is, however, expected to reach an estimated value of US$3.4 billion in 2019.
Erectile dysfunction is a very common medical disorder in men. It typically affects men older than 40 years in age and can be postulated as an age-related condition too. But at some point in time, men may also face erectile dysfunction due to psychological and physiological factors. According to the research led by the analysts at TMR, the global erectile dysfunction drugs market is mainly driven by a rise in incidences of various diseases, rising geriatric population, increasing focus on awareness and education, and shifting preference towards a sedentary lifestyle.
Moreover, the growing impact of clinical tests and trials for erectile dysfunction drugs contributes vastly to the growth in the erectile dysfunction drugs market. Some other areas that hold plenty of growth opportunities in this market are innovative drug delivery, blockbuster patent expirations, new test techniques, and molecule combinations. 
Three major erectile dysfunction drugs – Cialis (tadalafil), Viagra (sildenafil citrate), and Levitra/Staxyn (vardenafil) – have been studied in this research report. Some more branded drugs such as MUSE (medicated urethral systems for erection), Stendra/Spedra (avanafil), Zydena (udenafil), Mvix (mirodenafil) and Helleva (lodenafil) have also been covered in this study.
By revenue, Viagra (sildenafil citrate) accounted for the largest share – 45% of the total erectile dysfunction drugs market. But due to the expiration of patents of the Viagra drug particularly outside the U.S. in 2013, and also due to the loss of patent and marketing exclusivity of Levitra (vardenafil) by Bayer AG and Cialis (tadalafil) by Eli Lilly & Co. in Europe and many other countries, the overall market revenue is likely to decline over the forecast period.
However, due to an extended patent exclusivity till 2020, Viagra will continue to maintain a major revenue share in the U.S. market.
Other Reports By Transparency Market Research :
The market for Cialis (tadalafil) will also witness a decline in market revenue from 2013 to 2019. This market had accounted for the second largest share in 2012, at US$1,926.8 million, but is now declining at a CAGR of 12.6% in the forecast period.
The demand for erectile dysfunction drugs is continuously rising to cater to the needs of the increasing elderly population and other growing diseases including renal diseases, chronic disorders, hypertension, hormonal insufficiency, diabetes, and other neurological disorders.  
Forecasts state that by the end of 2019, the erectile dysfunction drugs market is expected to witness a major decline in the world. Owing to weak pipeline development the erectile dysfunction drugs market will experience a low success rate in the matters of new drug formulations as well.
Geographically, the North American market for erectile dysfunction drugs was valued at US$2,098.4 million in 2012 and is expected to continue to lead throughout the forecast period in terms of revenue generation.